Swedish Orphan Biovitrum AB (publ) (Sobi) today announced the appointments of
Krassimir Mitchev, MD, Ph.D., and Stefan Lethagen, MD, Ph.D. as two new senior
members joining the company's haemophilia team.
Dr. Mitchev has been appointed Vice President and Medical Therapeutic Area Head,
Haemophilia. He earned his medical and doctorate degrees from the University of
Sofia in Bulgaria and is specialised in internal and pulmonary medicine. Dr.
Mitchev brings more than 25 years of medical and scientific leadership
experience from senior roles at GSK and UCB Pharma, and from academic positions
at Erasme Hospital in Brussels and at University Hospital Sofia. Most recently
he was Medical Director at the Center of Excellence for Immunology and Hepatitis
at GSK, where he was responsible for the medical aspects of the Benlysta® launch
and for the collaboration with Human Genome Sciences.
"We are pleased to welcome Krassimir to Sobi", said Birgitte Volck, Senior Vice
President and Chief Medical Officer at Sobi. "With his strong medical and
scientific background as well as leadership experience from the industry
including a recent specialty launch and from working in cross-company
collaborations to secure patient access for new products, he is ideally suited
for the medical leadership role of the Haemophilia programs at Sobi."
Dr. Lethagen has been appointed Vice President Medical and Clinical Sciences,
Haemophilia. He received his medical and doctorate degrees from Lund University
in Sweden and specialised in internal medicine and haematology at Malmö
University Hospital. Dr. Lethagen was appointed Professor in Haemophilia and
Thrombosis at the Medical Faculty at Copenhagen University in 2006. He was a
founder and Chairman of the Nordic Haemophilia Council from 2007-2009. Stefan
joins Sobi from Novo Nordisk, where he served as International Medical Director,
Haemophilia, leading early clinical development programs.
"Stefan brings a prominent expertise to his role underlined by his clinical
academic credentials and co-authorship of more than 100 peer reviewed
publications and several book chapters related to haemophilia", continued Volck.
"Krassimir's and Stefan's individual and combined expertise will bring important
seniority and perspective to Sobi's haemophilia team as we prepare for the
possible launch of the recombinant long-acting haemophilia factors in
development with Biogen Idec."
Together with its partner Biogen Idec, Sobi currently has two on-going
paediatric phase III trials, KIDS A-LONG and KIDS B-LONG in addition to the on-
going open label extension studies from the registrational programmes. Both are
on track and Sobi expects to release top line data from these trials during
2014.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information - not for
publication
Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
Investor Relations
T: +46 70Â 410 71 80 T: +46 8 697 20 00
oskar.bosson@sobi.com jorgen.winroth@sobi.com
Sobi appoints Haemophilia medical leadership team:
http://hugin.info/134557/R/1738077/582983.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1738077]
